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Abstract
Background: Leishmaniasis caused by two new species of Leishmania; L. siamensis and L. martiniquensis have been
recently described in Thailand. The disease has mainly been documented in AIDS patients from southern Thailand.
In this study, polymerase chain reaction (PCR) was used to determine HIV-Leishmania co-infection in southern
Thailand.
Methods: One ml of saliva and 3 ml of EDTA blood were collected from HIV-infected patients for PCR detection
of Leishmania DNA, cloning and sequencing. The positive PCR samples were then cultured on Schneider’s insect
medium.
Results: Three out of 316 saliva samples collected from HIV-infected patients were found to be positive for Leishmania
DNA (0.95 %). Among the positive samples, one patient was observed with disseminated cutaneous lesions and also
tested positive via saliva, whole blood and buffy coat in PCR. The second case presenting with nodular lesions also
gave a positive saliva test via PCR two months prior to buffy coat. This diagnosis was confirmed by microscopic
examination and a culture of biopsy samples from a nodule. The last case was an asymptomatic Leishmania infection
which tested PCR positive only in saliva with a consecutive sample collection conducted for three months.
Conclusions: The prevalence of Leishmania infection in HIV infected patients within this study is 0.95 %. Leishmania
DNA was detected in saliva by PCR prior to blood and buffy coat of two HIV infected patients. Early detection of
Leishmania DNA in saliva would be beneficial for the follow up of asymptomatic Leishmania infected patients, the
early treatment of leishmaniasis and for surveillance survey purpose. However, full evaluation of sensitivity and
specificity of this technique with a large cohort of patients is required before deployment.
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Background
Autochthonous leishmaniasis cases in Thailand have
been increasingly diagnosed in recent years. The dis-
ease was described in both immunocompetent and im-
munocompromised patients, such as those with AIDS
[1] and in systemic steroid therapy [2]. Approximately
20 cases of autochthonous leishmaniasis have now been
documented, with most found in the south of Thailand
[1–9]. Sukmee and others first reported a suspected
new Leishmania species from Thailand (2008) [3] which
was named L. siamensis [7]. A report by Leelayoova et al.
(2013) [10] demonstrated that L. siamensis in Thailand
has two lineages: the PG lineage or PCM1 isolate (Acces-
sion no JX195640) [3] and TR lineage or PCM2 isolate
(Accession no EF200012) [7]. However, more recently
Pothirat et al. (2014) [11] identified a PCM1 and a new
isolate from northern Thailand LSCM1 (Accession no
JX898938) which are L. martiniquensis as described by
Desbois et al. (2014) [12], and only the PCM2 isolate was
identified as L. siamensis. They also reiterated that most
cases of leishmaniasis are caused by L. martiniquensis in
Thailand. More recently, Chiewchanvit et al. (2015) also
* Correspondence: amphumee@gmail.com
1Department of Parasitology, Faculty of Medicine, Chulalongkorn University,
Bangkok 10330, Thailand
Full list of author information is available at the end of the article
© 2016 Siriyasatien et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Siriyasatien et al. BMC Infectious Diseases  (2016) 16:89 
DOI 10.1186/s12879-016-1433-2
described a case of HIV and L. martiniquensis co-infection
in northern Thailand who presented with chronic general-
ized fibrotic skin lesions [13].
In other parts of the world such as isolates from Myanmar
patients (Accession no KF211417) [2], cows in Switzerland
(Accession no GQ281282), a horse in Germany (Accession
no GQ281278) and a horse in the USA (Accession no
JQ617283) [14–16] may be L. martiniquensis. Liautaud
et al. (2015) reported the first case of visceral leishmaniasis
caused by L. martiniquensis from the Caribbean [17].
This indicates that L. martiniquensis has a worldwide
distribution while L. siamensis is limited in its geographic
distribution.
Three clinical forms of these novel Leishmania species
have been described: visceral, disseminated cutaneous,
and combined disseminated cutaneous with visceral [1–9,
11, 13]. The disease has been described mostly in im-
munocompromised patients, especially those with
AIDS. Apart from L. martiniquensis and L. siamensis,
an autochthonous leishmaniasis case caused by L.
infantum was also reported from Thailand [18].
The prevalence of leishmaniasis in Thailand has never
been fully studied. Screening tests for leishmaniasis, such
as Enzyme-linked immunosorbent assay (ELISA), Direct
antiglobulin test (DAT) and rK39 dipsticks, are not gen-
erally available. Microscopic examination and culture are
time-consuming and require expertise to be reliable. Mi-
croscopy, culture and PCR are generally the methods of
choice used for diagnosis [1].
PCR has been developed to detect Leishmania DNA,
and Leishmania species were identified by a sequence
analysis [19–21]. PCR has high sensitivity and specificity
for detecting Leishmania DNA [22, 23] and has been
used for detection from various clinical samples includ-
ing blood, bone marrow, tissue, saliva, and urine [1–6].
Saliva has been shown to be a good source for the detec-
tion of the new Leishmania species DNA [1–6].
Several previous studies demonstrated that Leishmania
DNA and antibodies were present in oral secretions
and saliva, such as L. braziliensis DNA from Brazil [24],
L. donovani from China [25] and L. infantum from Tunisia
[26]. In Thailand, Phumee et al. (2013) demonstrated that
saliva is a good source for PCR detection of novel Leish-
mania species DNA in Thailand [1, 2, 4–6, 9]. They also
showed that the Leishmania DNA levels in saliva decreased
after treatment [1]. Saliva could be used as a biomarker to
detect the new Leishmania species infection. Furthermore,
the collection of saliva is non-invasive, requires no special
equipment, and is suitable for children and elders [27, 28].
The prevalence of the disease in Thailand has never
been fully investigated. This study’s objectives are to de-
termine the prevalence of Leishmania infection in HIV-
infected Thai patients from southern Thailand through
PCR analysis of saliva and blood samples.
Methods
Study design
The study was conducted in southern Thailand from
June to September 2013. A total of 316 HIV-infected pa-
tients who came for HIV treatment were enrolled in the
study at the Division of Infectious Diseases of Faculty of
Medicine, Prince of Songkla University. One ml of saliva
and 3 ml of EDTA blood were collected for PCR detec-
tion of Leishmania DNA.
Ethics approval
Informed consent was obtained from all subjects accord-
ing to protocols approved by the Institutional Review
Board on Human Research of the Faculty of Medicine,
Chulalongkorn University (COA No. 768/2012).
Study population
Blood and saliva samples were collected from HIV-infected
patients who resided in southern Thailand. A total of 316
HIV-infected patients involved in treatment at the Division
of Infectious Diseases were enrolled in the study.
DNA extraction
One ml of whole saliva was used to extract DNA from the
tissue using the Invisorb® Spin Tissue Mini Kit (STRATEC
Table 1 Clinical presentations, CD4+ T cell levels, PCR, and Culture/Tissue biopsy for Leishmania parasitea
Patient Clinical Presentation CD4+ T
cell count
(cells/mm3)







S B BF S B BF S B BF
32 year old Relapse disseminated CL 2 years after treatment 110 + + + Not collected Not collected +/+
Male
48 year old Nodular CL, relapse 2 years after treatment for
disseminated CL
207 + - - + - - + - + +/+
Male
28 year old Asymptomatic 617 + - - + - - + - - -/N/A
Female
aS Saliva; B Blood; BF Buffy coat; +: positive; −: Negative; N/A: not available; CL: Cutaneous leishmaniasis
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Molecular GmbH, Germany) according to the manufac-
turer’s instructions. To extract the DNA, 200 μl of EDTA
blood and 50 μl of buffy coat were used with the extraction
kit, Invisorb® Spin blood Mini Kit (STRATEC Molecular
GmbH, Germany). Extracted DNA was eluted in 50 μl of
elution buffer. The quantity and quality of the extracted
DNA were determined using a Nanodrop 2000c (Thermo
Scientific, Singapore). Extracted DNA samples were kept at
−80 °C for long-term storage.
PCR amplification
Amplification was performed in a PCR Mastercycler® pro
(Eppendorf, Germany) with conditions as follows; denatur-
ation at 94 °C for 4 min, followed by 40 cycles of 94 °C for
1 min’; 65 °C for 1 min; and 72 °C for 1 min, with the final
extension at 72 °C for 7 min. The forward and reverse
ITS1 regions of the rRNA of Leishmania parasite primers
were LeF: 5′ TCC GCC CGA AAG TTC ACC GAT A 3’
and LeR: 5′ CCA AGT CAT CCA TCG CGA CAC G 3’,
respectively [29]. In order to maintain that the template
DNA had been extracted properly, primers that anneal to
human DNA (UNFOR403: 5’-TGA GGA CAA ATA
TCA TTC TGA GG-3’ and UNREV1025: 5’-GGT TGT
CCT CCA ATT CAT GTT A-3’) were used [30].
Therefore, clinical samples which contain human DNA
should show the PCR products of 628 bps. The prod-
ucts were analyzed on 1.5 % agarose gel electrophoresis,
stained with 0.5 μg/ml ethidium bromide and visualized
with Quantity One quantification analysis software,
version 4.5.2 Gel Doc EQ system (Bio-Rad, USA). DNA
from cultured Leishmania promastigotes isolated from
a patient [5] was used as the positive control. DNA from
saliva and EDTA blood from a healthy individual who
had never traveled into endemic areas were used as
negative controls.
Cloning, sequencing and nucleotide analysis
The study was designed to use cloning for sequencing ra-
ther than direct sequencing because the ITS1 primers
used in this study can amplify closely L. martiniquensis
and L. siamensis at 379 and 371 bps, respectively. More-
over, PCR products obtained from some reactions con-
tained small amount of DNA, while direct sequencing
requires at least 30–50 ng/μl of DNA. Amplified PCR
products were ligated into pGEM-T Easy Vector (Pro-
mega, USA). The ligated vectors were transformed into
DH5α competent cells and screened through the blue-
white colony selection system. The suspected positive col-
onies were cultured for further plasmid DNA extraction
using the Invisorb® Spin Plasmid Mini kit (STRATEC Mo-
lecular GmbH, Germany), following the manufacturer’s
instructions. Purification was performed according to the
1st BASE DNA sequencing system (1st base laboratories,
Malaysia) using universal forward T7 primer. Nucleotide
sequences were analyzed using the BioEdit Sequence
Alignment Editor Version 7.0.9.0. The consensus se-
quences were compared with available sequence data
in GenBank using BLAST search (available at http://
blast.ncbi.nlm.nih.gov/Blast.cgi). Sequences obtained
from this study were submitted to GenBank to be
assigned accession numbers.
Fig. 1 Cutaneous leishmaniasis lesions of the patient 1
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Phylogenetic tree construction
A phylogenetic tree was constructed by Maximum-like-
lihood method using the Kimura’s 2-parameter model im-
plemented in MEGA6 version 6.06 and the tree was tested
using 1000 bootstrap replicates. ITS1 sequences of con-
firmed L. martiniquensis (KM677931) [10] and L. siamen-
sis (JX195640) [9] were used to compared with ITS1
sequences of our study. Bodo caudatus accession no.
AY028450 was used as an outgroup.
Culture of Leishmania parasite
Positive PCR samples were cultured on Schneider’s insect
medium (Sigma-Aldrich, USA), which contained 10 % fetal
bovine serum, 100 U/ml of penicillin, and 100 μg/ml of
streptomycin (Sigma-Aldrich, USA). The samples were then
incubated at 25 ± 2 °C. The promastigotes were observed
daily under an inverted microscopy (Olympus, Japan).
Tissue biopsy and staining
A tissue biopsy was performed on an ulcer or nodule
from the PCR-positive study patients. Tissue sections
were stained with Hematoxylin and Eosin (H&E) and
examined under a light microscope (Olympus, Japan) at
100X magnification.
Results
Saliva and blood samples were tested with Leishmania-
specific primers, ITS1 gene by PCR. Three of the 316 sal-
iva samples were positive for Leishmania species DNA
(0.95 %). Among these three positive cases, two had been
diagnosed as leishmaniasis two years previously (Table 1).
The first of these cases, involving a 32-year-old male, was
diagnosed for disseminated CL 2 years previously. He was
treated with amphotericin B deoxycholate and itraconazole,
following which his lesions regressed and all samples tested
by PCR were negative for Leishmania [1–6]. However, in
June 2013, he developed multiple papules and ulcers (Fig. 1).
A CD4+ T-cell count revealed 110 cells/mm3 and he was
started on tenofovir, lamivudine and nevirapine for treat-
ment of HIV. Saliva, whole blood, buffy coats, and tissue bi-
opsy were also positive for Leishmania DNA. Both culture
and H&E stains confirmed the recurrent diagnosis by
showing Leishmania in a skin biopsy (Table 1).
Two other cases were positive only in saliva from the
first PCR sample collected (Table 1). One of these cases
was a 48-year-old male who was diagnosed two years
previously with disseminated leishmaniasis [5] and was
treated with liposomal amphotericin B, followed by itra-
conazole. His clinical status improved and blood and sal-
iva samples were negative after treatment. He received
boosted lopinavir and lamivudine for HIV. Blood and
saliva samples were collected for a Leishmania PCR in
July 2013 with only saliva testing positive (Table 1 and
Fig. 2a). He developed nodules on his brow, left second
toe, left ring finger, and left elbow. His lesions were de-
scribed by Phumee et al. (2014) [9]. Blood and saliva
samples were then collected for two consecutive months
(August and September 2013). PCR was positive in buffy
coat and saliva samples two months after the first collec-
tion (September 2013), (Table 1 and Fig. 2a). A tissue bi-
opsy was performed at a nodule from his brow in
September 2013. A PCR of the biopsy sample was posi-
tive for the novel Leishmania species. (Table 1 and
Fig. 2a). The first and second cases of leishmaniasis re-
lapsed approximately 2 years after the treatment [5].
The last case was a 28-year-old female who was
asymptomatic but whose PCR was positive in saliva (July
2013) and had a CD4+ T-cell count of 617 cells/mm3.
Fig. 2 PCR amplification of the ITS1 gene against saliva, buffy coat, blood, and tissue samples of nodular leishmaniasis case (a) and asymptomatic
case (b). PCR amplicons were analyzed by electrophoresis on a 1.5 % agarose gel and stained with ethidium bromide. Lane S1, B1 and BF1: first
saliva, blood and buffy coat collection, respectively; lane S2, B2 and BF2:second saliva, blood and buffy coat collection, respectively; and lane S3,B3 and
BF3: third saliva, blood and buffy coat collection, respectively; T: tissue, lane M: molecular mass marker (100 basepairs [bp]); lane P: positive control
containing extracted DNA from cultured L. martiniquensis-produced fragments of 379 bp, lane N: negative control (no DNA template: double-distilled
water); lanes N1–N3: negative control (DNA template from non-infected saliva, blood, and buffy coat, respectively); and a PCR for template DNA control
shown below (628 bp)
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She did not receive any treatment for HIV. Blood and
saliva collected for two consecutive months (August and
September 2013) were negative, but PCR remained posi-
tive (Table 1 and Fig. 2b).
Amplified sequences obtained from saliva, blood, buffy
coat, and tissue of the patient 1 were assigned for accession
numbers KU050856-KU050859 respectively. Amplified se-
quences obtained from saliva, buffy coat, and tissue of
patient 2 were assigned for accession numbers KU050860-
KU050862, while the amplified sequence from saliva of
patient 3 was assigned accession number of KU050863.
The nucleotide sequencing of all PCR-positive samples
were 100 % identical to L. martiniquensis (Fig. 3a and b).
The UNFOR403 and UNREV1025 primers which were
annealed specifically to human DNA gave positive re-
sults for all clinical samples (Fig. 2a and b). This showed
that all extracted DNA from clinical samples were ex-
tracted properly.
Discussion
This study identified Leishmania co-infections in HIV
patients using saliva and blood samples for PCR within
Fig. 3 Sequence comparison between L. martiniquensis and L. siamensis, the different in size and sequences were observed. Red circle indicated
L. martiniquensis obtained from this study (a). A phylogenetic tree showed that both L. martiniquensis and L. siamensis were classified into L.
enriettii complex and were discriminate to other Leishmania species (b)
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an endemic area of Thailand. Three out of 316 saliva
samples were positive for PCR Prevalence of Leishmania
infection in HIV infected patients of this study was
0.95 %. In 2012, Orsini and others investigated preva-
lence of Leishmania infection among 381 HIV-infected
patients who living in endemic areas of Brazil. The re-
sults showed positive for Leishmania in blood samples by
using PCR targeted to kDNA region, ELISA, Indirect
fluorescent antibody test (IFAT), and rK39 at 6.3 %,
10.8 %, 3.9 %, 0.8 % [30] respectively. Comparing the PCR
results, the prevalence of Leishmania infection in HIV pa-
tients of our study is lower than the result reported by
Orsini et al. (2012) [31].
Interestingly in this study, Leishmania DNA was de-
tected in saliva prior to appearing in buffy coat in patient
two and was also detected only in saliva for patient three.
A definite diagnosis was confirmed using microscopy and
a culture of tissue biopsy from a nodular lesion. Sequence
analysis of amplified PCR products were 100 % identical
to L. martiniquensis (Accession no KM677931).
Sequence analysis demonstrated that the amplified ITS1
gene region in this study was able to discriminate between
L. martiniquensis and L. siamensis (Fig. 3a). Phylogenetic
tree construction showed that both L. martiniquensis and
L. siamensis were classified into the L. enriettii complex
(Fig. 3b), a result that is similar to that previously reported
by Pothirat et al. (2014) [11]. Again, similar to the result of
Pothirat et al. (2014) [11] which mentioned that most
cases of leishmaniasis in Thailand are caused by L. marti-
niquensis, all three cases of this study were also infected
by L. martiniquensis.
Patients infected with leishmaniasis in Thailand
often have diffuse cutaneous [7, 9], visceral leishman-
iasis [1, 3–8] or overlapping diffuse cutaneous and vis-
ceral forms [1, 5–9]. Two leishmaniasis cases of this study
were presented with cutaneous lesion, one case had dif-
fuse cutaneous lesion (Fig. 1) while another presented
with multiple nodular lesions [9].
This study also demonstrated the first asymptomatic L.
martiniquensis infection in Thailand. Clinical samples
were consecutively collected for two months. Leishmania
DNA was still detected only in the saliva of the asymp-
tomatic case. A study by Phumee et al. (2013) previously
demonstrated that Leishmania DNA was detected in sal-
iva and buffy coat in all of their cases [1]. However, in this
study we found that it was detected only in saliva two
months prior to buffy coat, in a patient presenting with
nodular leishmaniasis. More recently, Sriworarat et al.
(2015) also demonstrated that L. martiniquensis DNA was
present in saliva prior to blood sample via the use of loop
mediated isothermal amplification (LAMP) technique
[32]. In this study, Leishmania DNA was also detected
only in the saliva of an asymptomatic patient. HIV and
leishmaniasis co-infection has been previously reported
from Thailand [1, 3–9]. Most of these cases were diag-
nosed from bone marrow or tissue biopsies, and some
cases died soon after without therapy [1, 7].
Conclusions
Our findings showed that early detection of Leishmania
DNA was found when conducting a PCR from the saliva
of two HIV infected patients. This could result in the
closer follow up of asymptomatic infected patients and
lead to earlier treatment of symptomatic leishmaniasis
which could decrease morbidity and mortality rates. This
could aid the development of disease surveillance tools,
especially in asymptomatic cases therefore improving the
design of control strategies. However, before the technique
can be deployed, sensitivity and specificity of the test
should be evaluated with the larger number of patients.
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